New targeted therapy aims at Hard-to-Treat bile duct cancers
NCT ID NCT06413745
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This phase 2 trial tests an experimental drug called SHR-A1811 in people with advanced biliary tract cancer that has HER2 expression or amplification and has stopped responding to earlier treatments. The drug is an antibody-drug conjugate designed to deliver a chemotherapy-like payload directly to HER2-positive cancer cells. The study will measure how many patients' tumors shrink and how long that effect lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental antibody-drug conjugate called SHR-A1811 that targets HER2-positive cancer cells
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced biliary tract cancer whose tumors have HER2 alterations and who have run out of standard therapies.
- What could go wrong
- This is an early-phase trial with only 59 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors in many patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 EXPRESSION / AMPLIFICATION IN PATIENTS WITH BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital，Fudan University
Shanghai, Shanghai Municipality, 200032, China